These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22145270)

  • 1. The use of acetyl cholinesterase inhibitors and memantine in nursing home residents.
    Gorus E; Van Puyvelde K; Corremans V; Mets T
    Acta Clin Belg; 2011; 66(5):361-6. PubMed ID: 22145270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
    Blaszczyk AT; Mang BH; Garza H; Mathys M
    Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study.
    Havreng-Théry C; Oquendo B; Zolnowski-Kolp V; Krolak-Salmon P; Bertin-Hugault F; Lafuente-Lafuente C; Belmin J
    Alzheimers Res Ther; 2024 May; 16(1):117. PubMed ID: 38812028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study.
    Herrmann N; Cappell J; Eryavec GM; Lanctôt KL
    CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
    Pfeil AM; Kressig RW; Szucs TD
    Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease.
    Fillit H; Hofbauer RK; Setyawan J; Tourkodimitris S; Fridman M; Pejović V; Miller ML; Erder MH; Lyketsos C
    J Am Med Dir Assoc; 2010 Nov; 11(9):636-644. PubMed ID: 21029998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of dementia and use of anti-dementia drugs in nursing homes].
    Engedal K
    Tidsskr Nor Laegeforen; 2005 May; 125(9):1188-90. PubMed ID: 15880157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of memantine for the treatment of dementia.
    Lo D; Grossberg GT
    Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
    Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
    Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
    Lachaine J; Beauchemin C; Legault M; Bineau S
    Can J Psychiatry; 2011 Oct; 56(10):596-604. PubMed ID: 22014692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
    Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
    J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
    Frölich L; Schmitt B; Calabrese P; Diener H; Förstl H; Gertz HJ; Hallauer JF; Hampel H; Ihl R; Rieke K; Riepe M; Supprian T
    Dtsch Med Wochenschr; 2005 Feb; 130(8):408-12. PubMed ID: 15717252
    [No Abstract]   [Full Text] [Related]  

  • 18. Antipsychotic drug use among nursing home residents taking rivastigmine.
    Narayanan S; Beusterien KM; Thomas SK; Musher J; Strunk B
    J Am Med Dir Assoc; 2006 Jan; 7(1):12-6. PubMed ID: 16413429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment of dementia.
    Schwarz S; Froelich L; Burns A
    Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's treatment in nursing homes: room for improvement.
    Bright-Long L
    J Am Med Dir Assoc; 2006 Feb; 7(2):90-5. PubMed ID: 16461250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.